©2024 Stanford Medicine
FLT-PET Imaging of Brain Tumors in Children
Not Recruiting
Trial ID: NCT01244737
Purpose
Brain tumors are the leading cause of death from solid tumors in children. Tumor imaging is
important in the management of these tumors, but current imaging methods have limitations in
providing the necessary information for optimal treatment of these patients. The goal of this
study is to evaluate the potential utility of positron emission tomography (PET) with
3'-deoxy-3'-[F-18] fluorothymidine (18F-FLT) in the medical management of brain tumors in
children. Funding source - FDA Office of Orphan Product Development (OOPD)
Official Title
Phase 2 Study of [18F]FLT for PET Imaging of Brain Tumors in Children
Stanford Investigator(s)
Paul Graham Fisher, MD
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Eligibility
Inclusion Criteria:
- age 21 years or less
- capable of achieving imaging without need for sedation or anesthesia (typically age 8
years or greater, but there is no lower limit for age for eligibility)
- Karnofsky Performance Status of 50 or greater in subjects age 12 years or greater, for
age less than 12 years a Lansky play scale of 50% or greater
- Patients receiving steroids and/or anti-seizure medications are eligible
Exclusion Criteria:
- clinically active infection
- pregnancy or breast-feeding
- serious intercurrent medical illness
- require emergency surgical intervention that would be inappropriately delayed by
FLT-PET imaging
Intervention(s):
drug: [18F] FLT
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Leah White
650-725-4708